Innovative financing and reimbursement models can improve access to cell and gene therapies, addressing cost barriers and improving patient outcomes, said Joe DePinto, MBA, of McKesson.
Joe DePinto, MBA
Advertisement
Articles by Joe DePinto, MBA
Joe DePinto, MBA, of McKesson; Kathi Henson, MBA, of Orsini; and Natalie Bedford of McKesson discuss how Asembia's AXS25 Specialty Summit fosters collaboration among industry leaders, exploring technology trends to enhance specialty pharmacy and patient care delivery.
Advertisement
Latest Updated Articles
Cell and Gene Therapies Hold Promise, but Access Barriers PersistDecember 19th 2024
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5